Restructuring	6 Months Ended
Apr. 01, 2023
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure	(6) Restructuring During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services will be moved to the Company’s Newark, Delaware facility. In addition, research and development, sales and services support and administrative functions will be moved to the Newark, Delaware and Marlborough, Massachusetts facilities. The transition is expected to be completed by the third quarter of fiscal 2025. The majority of employees located in Danbury were given the option to relocate to the new locations. As a result of this plan, the Company expects a number of employees to not relocate resulting in their termination. The employees were notified of the closure during the first quarter of fiscal 2022 but were not informed of their termination and related severance benefits until the third quarter of fiscal 2022. The Company is recording severance benefits pursuant to pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420), and the severance benefits are being expensed ratably over the required service period. As a result, the Company recorded severance charges of $0.3 million and $1.0 million during the three and six months ended April 1, 2023, respectively, and $1.6 million in fiscal 2022. The Company estimates that total severance charges, including retention, will be approximately $5.5 million. During the first and second quarters of fiscal 2023, the Company made various decisions to consolidate and close certain offices in Germany and in connection with such actions to terminate certain individuals across all divisions in multiple departments. For the three and six months ended April 1, 2023, the Company recorded $1.5 million and $1.9 million, respectively, primarily for severance benefits related to these actions. These charges were recorded pursuant to ASC 712, Compensation-Nonretirement Postemployment Benefits (ASC 712) or ASC 420, depending on the employee. The Company estimates that total severance charges will be approximately $3.9 million, and the actions will be completed by September 2023.

Restructuring

6 Months Ended

Apr. 01, 2023

Restructuring and Related Activities Disclosure

(6) Restructuring

During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services will be moved to the Company’s Newark, Delaware facility. In addition, research and development, sales and services support and administrative functions will be moved to the Newark, Delaware and Marlborough, Massachusetts facilities. The transition is expected to be completed by the third quarter of fiscal 2025. The majority of employees located in Danbury were given the option to relocate to the new locations. As a result of this plan, the Company expects a number of employees to not relocate resulting in their termination. The employees were notified of the closure during the first quarter of fiscal 2022 but were not informed of their termination and related severance benefits until the third quarter of fiscal 2022. The Company is recording severance benefits pursuant to pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420), and the severance benefits are being expensed ratably over the required service period. As a result, the Company recorded severance charges of $0.3 million and $1.0 million during the three and six months ended April 1, 2023, respectively, and $1.6 million in fiscal 2022. The Company estimates that total severance charges, including retention, will be approximately $5.5 million.

During the first and second quarters of fiscal 2023, the Company made various decisions to consolidate and close certain offices in Germany and in connection with such actions to terminate certain individuals across all divisions in multiple departments. For the three and six months ended April 1, 2023, the Company recorded $1.5 million and $1.9 million, respectively, primarily for severance benefits related to these actions. These charges were recorded pursuant to ASC 712, Compensation-Nonretirement Postemployment Benefits (ASC 712) or ASC 420, depending on the employee. The Company estimates that total severance charges will be approximately $3.9 million, and the actions will be completed by September 2023.